Project title: Understanding the broader behavioural and social implications of the new generation of GLP-1 receptor agonist weight loss drugs
Lead researcher: Dr Jack Birch (Jack.Birch@newcastle.ac.uk)
Research team: Dr Fiona Graham, Dr Louise Tanner, Prof Daniel Read, Prof Clare Llewellyn, Prof Falko Sniehotta, Prof Angel Chater

Plain English summary
Obesity affects many people in the population. Recent estimates found that more than one in four adults in England live with obesity. The picture is similar across each of the countries in the United Kingdom.
Many interventions exist to help people to manage their weight. Some of these focus on changing people’s behaviours around their diet and physical activity. Alternatively, there are also drugs which can help people with obesity to lose weight.
There have been important recent developments in the drugs available for obesity. Two prominent examples are tirzepatide (also known as Mounjaro or Zepbound) and semaglutide (also known as Ozempic or Wegovy). These drugs can be accessed privately, including through pharmacies or online providers, or through the NHS. As these drugs are quite new, there are many areas where there is a current lack of evidence. This means that we are conducting a project that provides policymakers with needed evidence on some of the wider impacts these drugs are having on the healthcare system and on the population.
First, the roll out of these drugs to all who are eligible on the NHS could take up to 12 years. Therefore, those who are providing these drugs – such as GPs and Integrated Care Boards – need to be able to effectively communicate when people may receive these drugs, and what people can do to manage their weight in the meantime. To do this, we are reviewing existing literature to ensure communication around who can expect to receive these drugs – and when – is effective.
Second, these new drugs are being used by a wide range of people in the population. Even more intend to use them or are interested in using them. Therefore, will survey a group of people who represent the wider population. This survey will aim to understand actual or intended use of drugs like tirzepatide and semaglutide. It will also explore the acceptability of providing these drugs through the NHS to the general population.
Finally, we want to understand the attitudes of people who are using these drugs. This includes asking about how they are taking their prescription, and what other services or support they are using to manage their weight. We will explore this by interviewing people who have experience of obesity and using these drugs.
Background
There have been significant recent developments in the pharmaceutical treatments available for managing obesity in adults, particularly around Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have been used for managing type 2 diabetes. GLP-1 RAs provide the opportunity for greater weight loss when compared to behavioural intervention alone. The use of these drugs for obesity may stem the gradual upwards trend in obesity prevalence, which is estimated to be 26.2% in adults in England and is similar across the UK.(1)
Two predominant examples of the new generation of pharmaceutical treatments for managing obesity are tirzepatide (also known by brand names Mounjaro or Zepbound) and semaglutide (brand names: Wegovy or Ozempic). Data from trials suggest people with obesity lost significantly more weight on average (15-20% of their body weight) when taking these drugs which compares to 2-5% of body weight through behavioural intervention alone at 12-18 months follow up.(2,3) Both tirzepatide (December 2024) and semaglutide (March 2023) have received recent NICE recommendation as options for weight loss treatment alongside appropriate behavioural support for people with at least one weight-related condition and a BMI of at least 35kg/m² (or 30kg/m² if referred to specialist weight management service for semaglutide).(4,5)
These drugs are considered as one part of a ‘whole systems approach’ to addressing obesity, alongside addressing the underlying causes of obesity and continued behavioural support to help people to manage their weight. Although there is a sufficient evidence base to meet NICE’s thresholds for recommendation, the literature around the wider implications of these drugs – for individuals, the health care system, and wider society – is developing.
Research questions
1) How can intervention timelines and a tiered/prioritised approach to eligibility in the NHS be effectively communicated to the public? (Work package 1)
2) Understanding the social and personal determinants of public attitudes towards and actual or intended GLP-1 RA use (Work package 2)
3) How do people with obesity approach weight management, including wider service use, after not being offered a weight loss drug? (Work packages 2 & 3)
What are our methods?
We are using a combination of methods to explore our research questions.
In Work Package 1, we are conducting a rapid systematic review to understand how intervention timelines and a tiered/prioritised approach to eligibility in the NHS can be effectively communicated to the public. The PROSPERO record for this review can be found here: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261285366
In Work Packages 2 and 3, we will use a combination of survey and qualitative interviews to explore the above research questions.
Image – credit ECPO
References
- Department of Health and Social Care. Obesity Profile – Data | Fingertips. 2024. Accessed November 13, 2024. https://fingertips.phe.org.uk/profile/national-child-measurement-programme/data#page/4/gid/1938133368/pat/159/par/K02000001/ati/15/are/E92000001/iid/93088/age/168/sex/4/cat/-1/ctp/-1/yrr/1/cid/4/tbm/1
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945
- National Institute for Health and Care Excellence. Semaglutide for Managing Overweight and Obesity. Technology Approisal Guidance [TA875]. NICE; 2023. Accessed July 28, 2023. https://www.nice.org.uk/guidance/ta875
- National Institute for Health and Care Excellence. NICE describes how weight loss drug tirzepatide will be rolled out. NICE website: The National Institute for Health and Care Excellence. December 5, 2024. Accessed December 16, 2024. https://www.nice.org.uk/news/articles/nice-describes-how-weight-loss-drug-tirzepatide-will-be-rolled-out